Nguyen et al. identified PRMT1 as a potential therapeutic target in MM, showing that its expression is elevated in relapsed/refractory patients and that inhibition by MS023 impaired MM growth in vitro and in vivo [35]. Here, PRMT1 is linked to Miyoshi myopathy.